The present and the future in the diagnosis and management of celiac disease

被引:58
作者
Castillo, Natalia E. [1 ]
Theethira, Thimmaiah G. [1 ]
Leffler, Daniel A. [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Gastroenterol, Boston, MA 02215 USA
来源
GASTROENTEROLOGY REPORT | 2015年 / 3卷 / 01期
关键词
celiac disease; gluten-free diet; autoimmune diseases; GLUTEN-FREE DIET; LARAZOTIDE ACETATE; VILLOUS ATROPHY; DOUBLE-BLIND; PREVALENCE; GLIADIN; WHEAT; ORGANIZATION; PERMEABILITY; ASSOCIATION;
D O I
10.1093/gastro/gou065
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Celiac disease is an autoimmune enteropathy caused by gluten in genetically predisposed individuals. In celiac disease, adaptive and innate immune activation results in intestinal damage and a wide range of clinical manifestations. In the past, celiac disease was thought to result in signs and symptoms solely related to the gastrointestinal tract. Now, more than half of the adult population presents with extra-intestinal manifestations that can also be expected to improve on a gluten-free diet. For this reason, it is recommended that physicians have a low threshold of suspicion for celiac disease. Current knowledge of the immune pathogenesis of this autoimmune disease has served as a catalyst for the development of novel diagnostic tools and therapeutics. Over the years, highly sensitive and specific serological assays, in addition to genetic markers, have been found to target specific steps in the cascade pathway of celiac disease. Also the advent of the gluten challenge has enabled experts to design diagnostic algorithms and monitor clinical responses in clinical trials. The gluten challenge has provided substantial benefit in the advance of novel therapeutics as an adjuvant treatment to the gluten free diet. Generally, a strict gluten-free diet is highly burdensome to patients and can be limited in its efficacy. Alternative therapies-including gluten modification, modulation of intestinal permeability and immune response-could be central to the future treatment of celiac disease.
引用
收藏
页码:3 / 11
页数:9
相关论文
共 78 条
[1]   The global village of celiac disease [J].
Accomando, S ;
Cataldo, F .
DIGESTIVE AND LIVER DISEASE, 2004, 36 (07) :492-498
[2]   Tolerable amount of gluten for people with coeliac disease [J].
Akobeng, A. K. ;
Thomas, A. G. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 27 (11) :1044-1052
[4]  
[Anonymous], 2004, NIH Consens State Sci Statements, V21, P1
[5]   An Update on Celiac Disease Histopathology and the Road Ahead [J].
Bao, Fei ;
Green, Peter H. R. ;
Bhagat, Govind .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (07) :735-745
[6]   ORAL ENZYME THERAPY FOR CELIAC SPRUE [J].
Bethune, Michael T. ;
Khosla, Chaitan .
METHODS IN ENZYMOLOGY, VOL 502: PROTEIN ENGINEERING FOR THERAPEUTICS, PT A, 2012, 502 :241-271
[7]   HLA related genetic risk for coeliac disease [J].
Bourgey, Mathieu ;
Calcagno, Giuseppe ;
Tinto, Nadia ;
Gennarelli, Daniela ;
Margaritte-Jeannin, Patricia ;
Greco, Luigi ;
Limongelli, Maria Giovanna ;
Esposito, Oscar ;
Marano, Caterina ;
Troncone, Riccardo ;
Spampanato, Antonella ;
Clerget-Darpoux, Francoise ;
Sacchetti, Lucia .
GUT, 2007, 56 (08) :1054-1059
[8]   A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease [J].
Catassi, Carlo ;
Fabiani, Elisabetta ;
Iacono, Giuseppe ;
D'Agate, Cinzia ;
Francavilla, Ruggiero ;
Biagi, Federico ;
Volta, Umberto ;
Accomando, Salvatore ;
Picarelli, Antonio ;
De Vitis, Italo ;
Pianelli, Giovanna ;
Gesuita, Rosaria ;
Carle, Flavia ;
Mandolesi, Alessandra ;
Bearzi, Italo ;
Fasano, Alessio .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 85 (01) :160-166
[9]   The Canadian celiac health survey [J].
Cranney, Ann ;
Zarkadas, Marion ;
Graham, Ian D. ;
Butzner, J. Decker ;
Rashid, Mohsin ;
Warren, Ralph ;
Molloy, Mavis ;
Case, Shelley ;
Burrows, Vernon ;
Switzer, Connie .
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (04) :1087-1095
[10]  
Cronk Daniel R, 2006, Curr Surg, V63, P322, DOI 10.1016/j.cursur.2006.05.006